2-Amino-2-methylhept-6-enoic acid | 1196090-89-7

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 丙氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-Amino-2-methylhept-6-enoic acid
• CAS: 1196090-89-7
• 化学式: C₈H₁₅NO₂
• 分子量: 157.21
• InChiKey: AERCCJGORROTKW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Z-SELECTIVE OLEFIN METATHESIS OF PEPTIDES
  申请人：CALIFORNIA INSTITUTE OF TECHNOLOGY

  公开号：US20160185821A1

  公开（公告）日：2016-06-30

  The invention relates generally to the synthesis of modified amino acids and modified peptides in the presence of cyclometalated catalysts. The invention has utility in the fields of catalysis, organic synthesis, polymer chemistry, and industrial and fine chemicals chemistry.

  该发明通常涉及在环金属催化剂存在下合成改性氨基酸和改性肽。该发明在催化、有机合成、聚合物化学以及工业和精细化学品化学领域具有实用性。
• [EN] PEPTIDE INHIBITORS OF FOCAL ADHESION KINASE ACTIVITY AND USES THEREOF<br/>[FR] INHIBITEURS PEPTIDIQUES DE L'ACTIVITÉ DE KINASE D'ADHÉRENCE FOCALE ET UTILISATION ASSOCIÉES
  申请人：UNIV ARIZONA

  公开号：WO2021042064A1

  公开（公告）日：2021-03-04

  This disclosure provides peptides which have an affinity for the focal adhesion targeting (FAT) domain of focal adhesion kinase (FAK). In particular, the peptides are modified and derived from the sequence of the LD2 alpha helical domain of paxillin (e.g., LD2 peptides), the LD4 domain of paxillin (e.g., LD4 peptides), and CD8 peptides. These peptides are capable of blocking an interaction between paxillin and FAK, thereby inhibiting FAK activity related to FAK-paxillin interaction. The invention further provides uses for such peptides as therapeutics for the treatment of cancer and other diseases characterized with FAK activity and/or expression (e.g., fibrosis).

  本公开提供了对焦粘附激酶（FAK）的焦粘附靶向（FAT）结构域具有亲和力的肽。具体来说，这些肽经过修改并来源于paxillin的LD2α螺旋结构域序列（例如LD2肽）、paxillin的LD4结构域（例如LD4肽）和CD8肽。这些肽能够阻断paxillin与FAK之间的相互作用，从而抑制与FAK-paxillin相互作用相关的FAK活性。该发明进一步提供了这些肽作为治疗癌症和其他具有FAK活性和/或表达（例如纤维化）特征的疾病的治疗药物的用途。
• DISUBSTITUTED AMINO ACIDS AND METHODS OF PREPARATION AND USE THEREOF
  申请人：Aileron Therapeutics, Inc.

  公开号：US20140128581A1

  公开（公告）日：2014-05-08

  Provided are crystalline α, α-disubstituted amino acids and their crystalline salts containing a terminal alkene on one of their side chains, as well as optionally crystalline halogenated and deuterated analogs of the α, α-disubstituted amino acids and their salts; methods of making these, and methods of using these.

  提供了结晶的α, α-二取代氨基酸及其结晶盐，其中在它们的侧链之一上含有一个末端烯烃，以及可选的结晶卤代和氘代的α, α-二取代氨基酸及其盐的类似物；制备这些的方法，以及使用这些的方法。
• [EN] NEW STAPLED-PEPTIDES AND USES THEREOF<br/>[FR] NOUVEAUX PEPTIDES AGRAFÉS ET LEURS UTILISATIONS
  申请人：UNIV MONTPELLIER

  公开号：WO2018115400A1

  公开（公告）日：2018-06-28

  The present invention relates to peptidomimetic macrocycles comprising at least one macrocycle-forming linker and an amino acid sequence chosen from the group consisting of : i) an amino acid sequence with at least about 50%, 60%, 70%, 80%, 90%, or 95% sequence identity to a human sequence IRAK2 54-71 (SEQ ID N°1) and 100% identity with the amino acids in the positions 5-6, 9-11, 14-15 or ii) an amino acid sequence with at least about 50%, 60%, 70, 80%, 90%, or 95% sequence identity to a human sequence IRAKM 66-83 (SEQ ID N°2) and 100% identity with the amino acids in the positions 5-6, 9-11, 13-14, wherein the peptidomimetic macrocycle comprises an a-helix and at least two natural or two non-natural amino acids crosslinked by a macrocycle-forming linker. It also concerns method of preparation of said peptidomimetic macrocycles and uses thereof, pharmaceutical composition and uses thereof, in particular as inhibitors of inflammatory pathways.

  本发明涉及肽类模拟大环，包括至少一个大环形成连接物和从以下群组中选择的氨基酸序列：i）具有与人类序列IRAK2 54-71（SEQ ID N°1）至少约50％、60％、70％、80％、90％或95％序列同一性的氨基酸序列，并且在位置5-6、9-11、14-15具有100％同一性；或ii）具有与人类序列IRAKM 66-83（SEQ ID N°2）至少约50％、60％、70％、80％、90％或95％序列同一性的氨基酸序列，并且在位置5-6、9-11、13-14具有100％同一性，其中肽类模拟大环包括α-螺旋和至少两个天然或非天然氨基酸，由大环形成连接物交联。本发明还涉及所述肽类模拟大环的制备方法和其用途，制药组合物及其用途，特别是作为炎症途径的抑制剂。
• Means and methods for treating pseudomonas infection
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin

  公开号：EP2835135A2

  公开（公告）日：2015-02-11

  The present invention relates to a peptide or depsipeptide of formula (I)          (Y)kX1YZ1X2Z2(Y)m     (I), wherein X1 is an α-amino acid residue or an α-hydroxy acid residue of formula (IIa)          -A-CR1R2-CO-     (IIa), X2 is an α-amino acid residue or an α-hydroxy acid residue of formula (IIb)          -A-CR3R4-CO-     (IIb), wherein A is NH or O; R1 and R3 are independently selected from H, halogen such as F, substituted or unsubstituted C1 to C4 alkyl such as methyl, substituted or unsubstituted aryl and substituted or unsubstituted arylalkyl, aryl being a 5- or 6-membered ring with 0, 1, 2 or 3 heteroatoms, heteroatoms being selected from O, N and S, alkyl in said arylalkyl being C1 to C4 alkyl, said alkyl in said arylalkyl optionally being substituted, the term "substituted", when relating to R1 and R3, providing for, as valence permits, 1, 2, 3, 4, 5, 6, 7 or 8 substituents, said substituents being chosen from halogen such as F; R2 and R4 together are chosen to be substituted or unsubstituted n-alk-1,ω-diyl or substituted or unsubstituted n-alken-1,ω-diyl, ω being an integer number selected from 6, 7, 8, 9, 10, 11, 12, 13 and 14, the term "substituted", when relating to R2 and R4, providing for 1 or 2, in case of the substituents being halogen 1, 2, 3, 4, 5, 6, 7 or 8 substituents, said substituents being chosen from halogen such as F and C1 to C4 alkyl such as methyl, said C1 to C4 alkyl in turn optionally being substituted with, as valence permits, 1, 2, 3, 4, 5, 6, 7 or 8 substituents, said substituents being chosen from halogen such as F, and the double bond in said n-alken-1,ω-diyl being at any one of positions 1, 2, 3, 4,... and (ω-1); each occurrence of Y is independently selected to be an α-amino acid or α-hydroxy acid; k is an integer number selected from 0, 1, 2, 3, 4, 5, 6 and 7; m is an integer number selected from 1, 2, 3 and 4; Z1 is a polar or negatively charged α-amino acid or α-hydroxy acid; and Z2 is a an aliphatic hydrophobic α-amino acid or α-hydroxy acid; the N-terminus of said peptide or depsipeptide is free; protected, preferably acetylated; or conjugated, preferably to a cell-penetrating peptide or a lipid; and the C-terminus of said peptide or depsipeptide is free; protected, preferably amidated; or conjugated, preferably to a cell-penetrating peptide or a lipid.

  本发明涉及一种式（I）的肽或去肽 (Y)kX1YZ1X2Z2(Y)m (I)、 其中 X1 是式（IIa）的α-氨基酸残基或α-羟基残基 -A-CR1R2-CO-(IIa)、 X2 是式（IIb）的α-氨基酸残基或α-羟基酸残基 -A-CR3R4-CO-（IIb）、 其中 A 为 NH 或 O；R1 和 R3 独立地选自 H、卤素如 F、取代或未取代的 C1 至 C4 烷基如甲基、取代或未取代的芳基和取代或未取代的芳烷基，其中芳基是具有 0、1、2 或 3 个杂原子的 5 或 6 元环，杂原子选自 O、N 和 S，所述芳烷基中的烷基为 C1 至 C4 烷基，所述芳烷基中的烷基可选择被取代，术语 "取代 "在涉及 R1 和 R3 时，在价位允许的情况下，可提供 1、2、3、4、5、6、7 或 8 个取代基，所述取代基可选自卤素，如 F；R2 和 R4 一起被选作取代或未取代的 n-烷-1,ω-二基或取代或未取代的 n-烯-1,ω-二基，ω 是选自 6、7、8、9、10、11、12、13 和 14 的整数，术语 "取代的 "在涉及 R2 和 R4 时为 1 或 2，在取代基为卤素的情况下为 1、2、3、4、5、6、7 或 8 个取代基、所述取代基选自卤素（如 F）和 C1 至 C4 烷基（如甲基），所述 C1 至 C4 烷基在价位允许的情况下可选择被 1、2、3、4、5、6、7 或 8 个取代基取代，所述取代基选自卤素（如 F），且所述正烯烃-1,ω-二基中的双键位于 1、2、3、4、...和 (ω-1)中的任一个位置；Y 的每一次出现都独立地被选作 α-氨基酸或 α-羟基酸；k 是选自 0、1、2、3、4、5、6 和 7 的整数；m 是选自 1、2、3 和 4 的整数；Z1 是极性或带负电荷的 α-氨基酸或 α-羟基酸；Z2 是脂肪疏水的 α-氨基酸或 α-羟基酸；所述肽或去肽的 N-末端是游离的；受保护的，最好是乙酰化的；或共轭的，最好是与细胞穿透肽或脂质共轭的；所述肽或去肽的 C-末端是游离的；受保护的，最好是酰胺化的；或共轭的，最好是与细胞穿透肽或脂质共轭的。